WebDec 31, 2024 · Investor Relations $654MM Full Year 2024 Revenue $187MM Full Year 2024 Adjusted EBITDA 26.4MM Average Monthly Visitors, Full Year 2024 19,506 Dealer Customers as of December 31, … WebInvestor Information. For Investor Relations information, including Annual Reports, SEC filings, and the most recent earnings release, please contact us via email. For other issues or clarification, securities analysts and investors are invited to contact Jeff Edwards, Managing Director, Head of Investor Relations, at 415-667-1524.
CHRS - Coherus BioSciences Inc Stock Price Quote
WebINTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Overview (Annual Report) 2024 Annual Report (707 KB) Overview (Safe-Harbor) View … Web04:30pm, Saturday, 26'th Feb 2024 Marketing Sentinel. In last trading session, Coherus BioSciences Inc. (NASDAQ:CHRS) saw 0.65 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $11.73 trading at $0.27 or 2.36% at ring of the bell on the day assigns it a market valuation of $939.46M. porsche in the glen
HOME - Chuan Huat Resources Berhad
WebAtrato Group. May 2024 - Present11 months. London, England, United Kingdom. Atrato Group is an alternative investment management and advisory group specialising in long term investment strategies that provide stable, predictable, non-cyclical returns. We advise, arrange and make principal investments across the asset backed long income spectrum. Webby marketingsentinel.com - 12-03. Coherus BioSciences Inc. (NASDAQ:CHRS)’s traded shares stood at 0.73 million during the last session, with the company’s beta value hitting 1.01. At the close of trading, the stock’s price was $6.93, to imply an increase of 3.59% or $0.24 in intraday trading. WebApr 11, 2024 · A high-level overview of Coherus BioSciences, Inc. (CHRS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. porsche in the glen 2022